ArticleGene therapy2005
Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy.
Article in Gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 50 citations in OpenAlex.
- MRI detection of the malignant transformation of stem cells through reporter gene expression driven by a tumor-specific promoter.Stem cell research & therapy · 2021Article
- Use of the XRCC2 promoter for in vivo cancer diagnosis and therapy.Cell death & disease · 2018Article
- Construction of a pIX-modified Adenovirus Vector Able to Effectively Bind to Nanoantibodies for Targeting.Acta naturae · 2014Article
- MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.PloS one · 2014Article
- Mesothelin-targeted agents in clinical trials and in preclinical development.Molecular cancer therapeutics · 2012Review
- Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Chapter two--Adenovirus strategies for tissue-specific targeting.Advances in cancer research · 2012Review
- Article
- Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Journal of oncology · 2012Article
- Retargeting of viruses to generate oncolytic agents.Advances in virology · 2012Article
- A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect.Human reproduction (Oxford, England) · 2010Article
- Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice.Cancer research · 2009Article
- Article
- Human dendritic cells infected with an adenoviral vector suppress proliferation of autologous and allogeneic T cells.Immunology · 2008Article
- Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells.Cancer biology & therapy · 2008Article
- Antigen-specific immunotherapy of cervical and ovarian cancer.Immunological reviews · 2008Review
- Mesothelin targeted cancer immunotherapy.European journal of cancer (Oxford, England : 1990) · 2008Review
- Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2006Article
- Transductional targeting of adenovirus vectors for gene therapy.Cancer gene therapy · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Adenoviruses (Ads) are efficient gene transfer vehicles, but Ad-mediated gene therapy for ovarian cancer remains limited in vivo by inefficient and nonspecific gene transfer. Mesothelin (MSLN), a cell surface glycoprotein, is overexpressed in ovarian cancer but not in normal tissues except mesothelial cells. Therefore, MSLN is an attractive candidate for transcriptional and transductional targeting in the context of ovarian cancer gene therapy. We evaluated the expression of MSLN mRNA and MSLN surface protein in ovarian cancer cells. Ads containing the MSLN promoter driving reporter gene expression were created and tested in ovarian cancer cell lines and purified ovarian cancer cells isolated from patients. To evaluate transductional targeting, we used an Ad vector containing an Fc-binding domain within the fiber protein, which served as a docking domain for binding with anti-MSLN immunoglobulins. Both RT-PCR and flow cytometry revealed high MSLN gene and protein expression in ovarian cancer cells. The MSLN promoter was activated in ovarian cancer cells, but showed significantly reduced activity in normal control cells. Transductional targeting of Ads via anti-MSLN antibody increased transgene expression in ovarian cancer cells. This report describes the use of MSLN for transcriptional as well as transductional targeting strategies for ovarian cancer gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.